Results 171 to 180 of about 360,869 (356)

SPARK: A webserver for comprehensive search and analysis of testicular single‐cell transcriptomic data covering full lifecycle and pathology

open access: yesiMetaOmics, EarlyView.
SPARK is an interactive platform hosting 189,232 human testicular single‐cell transcriptomes across normal and infertile conditions. It enables automated, code‐free analysis and visualization, providing a powerful resource to explore cellular and molecular dynamics in male reproduction and infertility.
Lina Cui   +9 more
wiley   +1 more source

What’s Up in Urology Journal, Spring 2011?

open access: yesUrology Journal, 2011
Urology Journal
doaj  

Steerable versus Conventional flexible and navigable suction ureteral access sheath (FANS) flexible Ureteroscopy for Lower Pole stones Treatment: study protocol for a multicentre, randomised superiority trial (SCULPT trial). [PDF]

open access: yesBMJ Open
Yuen SKK   +30 more
europepmc   +1 more source

Urological Reflections [PDF]

open access: yesProceedings of the Royal Society of Medicine, 1946
openaire   +2 more sources

Inflammatory bowel disease and metabolic reprogramming: From pathological mechanisms to targeted interventions

open access: yesInterdisciplinary Medicine, EarlyView.
This review explores the role of metabolic reprogramming in inflammatory bowel disease (IBD) by focusing on immune and epithelial cell metabolism, microbial metabolites, and their impact on inflammation. It discusses emerging metabolic therapies and emphasizes the importance of personalized microbiota‐targeted approaches to improve clinical outcomes in
Zemin Tian   +6 more
wiley   +1 more source

What’s Up in Urology Journal, Spring 2010?

open access: yesUrology Journal, 2010
Urology Journal
doaj  

Practice bulletin on the diagnosis of female stress urinary incontinence in France from the Committee of Female Urology (CUROPF) of the French Association of Urology (AFU)

open access: hybrid
B. Peyronnet   +18 more
openalex   +1 more source

Population Pharmacokinetics Analysis of Talazoparib and Enzalutamide Combination Therapy for Patients With Metastatic Castration‐Resistant Prostate Cancer

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract The poly(ADP‐ribose) polymerase inhibitor talazoparib, combined with the androgen receptor inhibitor enzalutamide is approved for patients with homologous recombination repair (HRR) gene‐mutated metastatic castration‐resistant prostate cancer (mCRPC) in the US and with mCRPC in whom chemotherapy is not clinically indicated in Europe.
Mark Hadigol   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy